Skip to main content

Merck, BGI Team on Biomarker Discovery

NEW YORK (GenomeWeb News) – Merck and BGI announced today that they will collaborate on the discovery and development of biomarkers and other genomic technologies.

The alliance combines Merck's expertise in drug discovery and development with BGI's sequencing and analytical capabilities.

Under the agreement, Whitehouse Station, NJ-based Merck and Shenzhen, China-based BGI can each propose projects to be undertaken. They also will each provide resources, expertise, samples, and other research materials needed for the collaboration.

"By working together we hope to apply BGI's comprehensive next-gen sequencing solutions to develop important new tools to aid drug development and enable effective tailoring of medicines to those patients most likely to respond," Jeffrey Chodakewitz, VP of late stage development at Merck Research Laboratories, said in a statement.

"This collaboration will bring mutual benefits to BGI and Merck in the next few years, but also support the development of new techniques that will benefit the medical and pharmaceutical industries as a whole," Ye Yin, president of the research and cooperation division of BGI, added.

Financial and other terms of the agreement were not disclosed.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.